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Introduction
Prostate cancer (PCa) is a slow-growing, organ-confined tumor
usually accompanied with a favorable overall prognosis. Current
standard-of-care chemotherapy, and recently immunotherapies, for
patients suffering from this disease may prolong overall survival and
improve quality of life, but they do not prevent tumor recurrence and
thus are not curative. Underlying reasons are not completely
understood. Recent investigations support a possible carcinogenic
activity of the human BK polyomavirus (BKPyV) in the prostate. In
this commentary, we envisage the development of BKPyV-related
therapeutic strategies to be beneficial for individuals at risk of
developing PCa.
For 2015, the American Cancer Society predicted that prostate
cancer (PCa) would account for 26% (220,800) of all new cancer cases
in men and for 9% (27,510) of all male cancer deaths in the United
States [1]. The high incidence-to-mortality ratio predominantly reflects
the favorable prognosis of localized disease, which is often curable with
surgery/radiation. Recurrence occurs in 20%-30% of the patients [2].
For these cases, androgen deprivation therapy is most likely effective,
but a large proportion eventually develops a hormone-independent
disease that often progresses to castration-resistant prostate cancer
(CRPC). Current chemotherapy and immunology-based therapies for
CRPC may prolong survival and quality of life but are not curative [3].
Chemotherapy is the treatment of choice after second and third-line
hormone ablation therapy. First-line chemotherapy with docetaxel and
prednisone was considered the standard-of-care for CRPC with
detectable metastatic disease [4]. Therapeutic interventions at the
immunological level have also been explored for the treatment of PCa.
For instance, autologous dendritic-cell-based agents (Sipuleucel-T),
whole cell- (GVAX) and PSA-targeted viral vector-based (PROSTVAC)
agents have been extensively studied in the context of metastatic CRPC
[5]. Although these emerging treatments provided better results in
terms of efficacy in phase II clinical trials, as compared to standard
chemotherapeutic treatments, they did not yield satisfactory
progression-free survival and hazard ratio (HR) of death in phase III
trials [5]. Nevertheless, cancer immunotherapy is a promising lead [5].
Taken together, new therapies that more specifically reduce the risk of
PCa progression are urgently needed. Here, we propose to address
these needs by generating specific tools targeting viral agents involved
in the genesis of PCa, such as BK polyomavirus (BKPyV). We envision
corresponding therapies to be especially effective in a preemptive
regimen when initiated following removal of the primary tumor, prior
to the establishment of gross metastases.
The oncogenic potential of BKPyV is mainly due to the activity of its
regulatory protein Large T antigen (LTag). The antigen is primarily
involved in the initiation of the proliferation of the virus as soon as
permissive cells are infected [6]. Beside its major activity in viral
replication, LTag also binds to and inactivates the products of tumor
suppressor genes, such as Retinoblastoma family proteins (pRb) and,
particularly, p53 [6]. In non-permissive cells, in which an abortive
infection takes place (by uncoupling of early gene expression from late
gene expression), the LTag binding to pRb and p53 triggers a
carcinogenetic process [7], as observed in vitro and in vivo in animals
[8]. In humans, the only evidence on the involvement of this virus in
the neoplastic process of the prostate is given by its detection at pre-
early stages of PCa, such as the proliferative inflammatory atrophy [9,
10].
The detection of the virus at molecular levels in tumor specimens
correlates with BKPyV-specific immune responses that might be
involved in the progression of PCa [11]. Indeed, in PCa patients with
evidence of disease recurrence and BKPyV-positive tumors, the LTag
induced an immune tolerogenic response able to sustain the
malignancy and favor a bad prognosis [12]. Therefore, exploiting the
immunogenic activity of LTag in PCa patients with a BKPyV-driven
tolerogenic signature is of utmost importance. We are thus currently
working on the generation of a vaccinia vector encoding immunogenic
peptides within BKPyV LTag, which are able to revert the regulatory
profile enhanced by specific portions of BKPyV LTag [13]. In addition,
we recently found that the antibody response to LTag might play a
central role in informing about the prognosis of this malignancy.
Indeed, the preoperative BKPyV LTag serostatus of patients
undergoing surgery at first diagnosis might act as an independent
predictor of biochemical recurrence and serve as a promising novel
therapeutic approaches targeting LTag [14].
Owing to its function, LTag localizes to the nucleus of infected cells.
In abortive infections, the presence of the LTag/p53 complex in the
cytoplasm of transformed cells is a peculiar sign [15]. By the
accumulation of LTag in the cytoplasm this antigen becomes an
immunogenic determinant which is able to provide effective cellular
and humoral immunosurveillance against infected cells [16]. In
addition, LTag production is regulated by viral microRNAs [17].
Indeed, the latter could not only control LTag expression but also
modulate its antigenic activity [18].
Therefore, targeting BKPyV LTag may lead to innovative
approaches in the treatment of PCa based on sound immunological
findings in either preventive or therapeutic settings.
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